Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p < 0.0001) and 66.0% response rate for non-menstrual pelvic pain...
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Purchases 70,000 Shares
09:54am, Wednesday, 22'nd Apr 2020
Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo acquired 70,000 shares of the company’s stock in a transaction on Friday, April 17th. The shares were acquired at an ave
Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Buys 50,300 Shares
09:22am, Wednesday, 22'nd Apr 2020
Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo bought 50,300 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was acquired at an avera
Against backdrop of shelter-in-place, Peninsula biotech asks FDA to approve prostate cancer drug
09:52pm, Tuesday, 21'st Apr 2020
Filing thousands of pages of data electronically from remote locations as employees sheltered in place against COVID-19, Myovant Sciences asked regulators Tuesday to quickly approve its once-a-day pil
BASEL, Switzerland, April 21, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced it.
BASEL, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health...
Myovant files U.S. application for relugolix for prostate cancer
01:11pm, Tuesday, 21'st Apr 2020
Myovant Sciences (NYSE:MYOV) has submitted a marketing application to the FDA seeking approval to use oral relugolix (120 mg) to treat men with advanced prostate cancer.It plans to file another applic
Myovant Sciences submits NDA to FDA for once-daily, oral relugolix MYOV
01:01pm, Tuesday, 21'st Apr 2020
Myovant Sciences submits NDA to FDA for once-daily, oral relugolix MYOV
BRIEF-Myovant Sciences Submits New Drug Application To The FDA For Relugolix
12:55pm, Tuesday, 21'st Apr 2020
Myovant Sciences Ltd:
Myovant Sciences (MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and
Myovant Sciences (NYSE:MYOV) Cut to "Buy" at ValuEngine
06:44am, Tuesday, 21'st Apr 2020
Myovant Sciences (NYSE:MYOV) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports. MYOV has
Heavy Menstrual Bleeding (HMB) Industry Insights & Epidemiology, 2017-2028 - ResearchAndMarkets.com
01:20pm, Monday, 20'th Apr 2020
The "Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
Daily Insider Ratings Round Up 4/17/20
12:35pm, Monday, 20'th Apr 2020
Tables of the top insider purchases and sales filed with the SEC on 4/17/20, based on dollar value. Dollar values often do not equate with significance when it
Myovant Sciences Ltd (NYSE:MYOV) Shares Bought by Goldman Sachs Group Inc.
10:02am, Monday, 20'th Apr 2020
Goldman Sachs Group Inc. grew its holdings in shares of Myovant Sciences Ltd (NYSE:MYOV) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5
Insider Buying: Myovant Sciences Ltd (NYSE:MYOV) Major Shareholder Buys $733,600.00 in Stock
08:52am, Monday, 20'th Apr 2020
Myovant Sciences Ltd (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo acquired 70,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was acquired at an
